TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00995046

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FVIII
Description: 6 months of prophylaxis treatment administered 3 or 4 times weekly according to patient's initial regimen, (standardized Malmö protocol 25 - 40 IU/kg/infusion). Medical visits will occur at 3-month intervals (+ 5 days) until the end of the study. Weekly, telephone calls to the patients (parents) will also be done.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FVIII
Description: 1 month period where thrombin generating capacity will be evaluated, followed by 6 months of individually tailored prophylaxis regimen according to TGT results. Medical visits will occur at 3-month intervals (+ 5 days) until the end of the study. Weekly, telephone calls to the patients (parents) will also be done.
Study: NCT00784238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone
Description: Paliperidone ER oral tablet will be administered once daily at a starting dose of 6 milligram (mg) for 24 weeks, wherein dose range will be 3 to 12 mg per day.
Study: NCT04283344

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: KY Ticket to Healthy Food Benefits
Description: Households in the treatment group received an extra monthly SNAP benefit amount through two new intervention-related deductions to the SNAP benefit formula
Study: NCT04439006

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive usual care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO
Study: NCT02653040

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamic lighting
Description: Intervention is rooms with light settings imitating natural light conditions with white light at day and low-lux no-blue light at night:~07am-10am: white light, increasing intensity 10am-07pm: white light, full intensity 07pm-11pm: no blue wavelength, low intensity 11pm-07am: no blue wavelength, very low intensity
Study: NCT00358150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eliglustat tartrate
Description: Eliglustat (Genz-112638) capsule as single 50 mg dose on Day 1 then eliglustat 50 mg twice daily (BID) from Day 2 to Day 19, then either eliglustat 50 mg BID (if Genz-99067\[active moiety of eliglustat in plasma\] trough plasma concentration was greater than or equal to \[\>=\]5 nanogram per milliliter \[ng/mL\] on Day 10) or eliglustat 100 mg BID(if Genz-99067 trough plasma concentration was less than \[\<\] 5 ng/mL), from day 20 to Year 4. After primary completion date (Week 52) participants underwent treatment interruption period of approximately 2 weeks before continuing same treatment through study completion (Year 9). Participant receiving 100 mg BID could be considered for further dose increase to 150 mg BID at Week 24 if they met certain criteria (for example, had been on treatment for at least 24 months, had not reached therapeutic goals established for participants receiving Cerezyme, and if all other causes for lack of treatment effect had been evaluated and ruled out).
Study: NCT00969345

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Stretching Exercises
Description: Conducted twice a week, with instructions for home exercises twice a day, and registering each session on a log sheet.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Respiratory Exercises conducted twice a day for 10 minutes
Description: Conducted twice a week, with instructions for home exercises twice a day, and registering each session on a log sheet.
Study: NCT01824563

Intervention type: OTHER
Intervention: Observational study
Study: NCT03072381

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Platelet Rich Plasma - Group 1
Description: Subjects in Group 1 (PRP) will receive a single ultrasound-guided intratendinous (common extensor tendon origin) injection of up to 3 mL autologous PEAK platelet-rich plasma at week 0 (baseline).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Corticosteroid Control - Group 2
Description: Subjects in Group 2 (corticosteroid control) will receive a single ultrasound-guided intratendinous injection approximately (may be limited by tendon/soft tissue limitations of the subject) of 2 mL 1% lidocaine + 1mL of him 40mg Kenalog (triamcinolone hexacetonide, 40mg/mL) at week 0.
Study: NCT03249376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumateperone
Description: Lumateperone 42 mg (ITI-007 60 mg tosylate)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01829893

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: In combination of 0.2mg finasteride and 5mg tamsulosin
Description: oral medication with 240 mL water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GL2701 capsule
Description: oral medication with 240 mL water
Study: NCT03893825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TV-46000
Description: TV-46000 will be administered per dose and schedule specified in the arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TV-46000
Description: TV-46000 will be administered per dose and schedule specified in the arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching to TV-46000 will be administered per schedule specified in the arm description.
Study: NCT04161807

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nerivio
Description: The device delivers transcutaneous electrical stimulation to the upper arm to induce conditioned pain modulation (CPM) that activates a descending endogenous analgesic mechanism. The treatment is self-administered and controlled by a smartphone application.
Study: NCT02123537

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bioness L300 Foot Drop System
Description: Participants will use the Bioness L300 Foot Drop System during waking hours for 12 weeks.
Study: NCT00946179

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza virus (split virion, inactivated) vaccine
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza virus (split virion, inactivated) vaccine
Description: 0.5 mL, Intramuscular
Study: NCT01852656

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Postcard and IVR Reminder Group
Description: IVR: Subjects in this reminder group will receive an automated telephone call to their primary telephone number. A total of 2 call attempts per member will be made. The IVR system will provide a message about the importance of annual influenza vaccination. The member can also request additional information about influenza vaccination and influenza vaccination locations and times.~Postcard: The postcard will be sent as a single postcard to each individual on the list. The postcard will be sent to the home address of the member. If the postcard is returned, the postcard will not be re-sent. The postcard does not identify that the member has a chronic health condition such as asthma or COPD. The postcard will be mailed during the last two weeks of September, 2012.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Postcard Only Reminder Group
Description: Postcard: The postcard will be sent as a single postcard to each individual on the list. The postcard will be sent to the home address of the member. If the postcard is returned, due to an inaccurate address, the postcard will not be re-sent. The postcard does not identify that the member has a chronic health condition such as asthma or COPD. The postcard will be mailed during the last two weeks of September, 2012.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: IVR Only Reminder Group
Description: IVR: Subjects in this reminder group will receive an automated telephone call to their primary telephone number. A total of 2 call attempts per member will be made. The IVR system will provide a message about the importance of annual influenza vaccination. The member can also request additional information about influenza vaccination and influenza vaccination locations and times.
Study: NCT01405755

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Appropriate complementary feeding messages
Description: Messages delivered through National Vaccine Program and radio
Study: NCT05278052

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Local consolidative radiation therapy
Description: Local consolidative radiation therapy (LCRT) to all oligo-metastatic sites in addition to primary disease site

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard maintenance therapy as decided by the treating medical oncologist
Description: Standard maintenance therapy/Observation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard maintenance therapy as decided by the treating medical oncologist
Description: Standard maintenance therapy/Observation
Study: NCT04139148

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ture Transcranial Direct Current Stimulation (tDCS)
Description: Ture 1-2 mA current of tDCS intervention in patients' binary brain DLPFC areas(20 mm).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Direct Current Stimulation (tDCS)
Description: Sham tDCS intervention in patients' binary brain DLPFC areas(20 mm).
Study: NCT01967264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Udenafil
Description: Udenafil tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Udenafil
Description: Udenafil tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Udenafil
Description: Udenafil tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets
Study: NCT01566630

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to RLX030 as intravenous infusion for 72 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLX030
Description: RLX030 1 mg/mL vials
Study: NCT03562546

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength From Within
Description: A 12 week at home structured resistance exercise programme using resistance bands. Participants will also receive a walking programme, a warm up and cool down, and ankle range of motion exercises.
Study: NCT02104830

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Empegfilrastim 6 mg
Description: Empegfilgrastim is supplied as solution for injection 3 mg/ml. Empegfilgrastim is to be administered 24 h after the chemotherapy at dose of 6 mg.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Filgrastim
Description: Filgrastim should be administered no earlier than 24 hours after the administration of cytotoxic chemotherapy. Filgrastim should be administered daily for up to 2 weeks until the ANC has reached 10 000/mm3 following the expected chemotherapy-induced neutrophil nadir.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo №1
Description: Placebo №1 is supplied as solution for injection 1.0 ml. Placebo №1 is to be administered 24 h after the chemotherapy at dose of 1.0.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo №2
Description: Placebo №2 should be administered no earlier than 24 hours after the administration of cytotoxic chemotherapy. Placebo №2 is supplied as solution for injection 0.0083 ml/kg.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo №2
Description: Placebo №2 should be administered no earlier than 24 hours after the administration of cytotoxic chemotherapy. Placebo №2 is supplied as solution for injection 0.0083 ml/kg.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Empegfilrastim 7.5 mg
Description: Empegfilgrastim is supplied as solution for injection 3 mg/ml. Empegfilgrastim is to be administered 24 h after the chemotherapy at dose of 6 mg.
Study: NCT04022837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole 40mg
Description: effect of this drug on renal function

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole 40mg
Description: effect of this drug on renal function
Study: NCT02765490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-335
Description: AL-335 800 mg (2\*400) tablet will be administered once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-335
Description: AL-335 800 mg (2\*400) tablet will be administered once daily.
Study: NCT01092819

Intervention type: OTHER
Intervention: Current standard of care for acute ischemic stroke other than IV rtPA or other IA therapies
Description: The objective of this study is to determine the natural history of acute ischemic stroke from large vessel thromboembolism in the brain. Patients with current standard of care other than IV rtPA or IA therapies will be studied.
Study: NCT05657600

Intervention type: BEHAVIORAL
Intervention: Sociodemographic profile, quality of life, sleep, fatigue, physical function and balance assessments
Description: Respiratory functions are assessed with a portable spirometer according to the criteria of the American Thoracic Society and European Respiratory Society. Measures the physical, mental, social, and environmental well-being were tested to understand the quality of life. The quality of sleep, delayed sleep, sleep disorders, usage of sleeping pills, and loss of functionality during the day were assessed. The balance and static standing capability of the participants were tested. The functional reach of participants were tested by expecting them to lean forwardly as far as they can without taking a step, nor rising their heels. The fatigue feeling of the participants as everyday life were assessed. The posture of the participants was assessed on 13 regions at anterior, posterior and lateral views.
Study: NCT02765490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Odalasvir
Description: Odalasvir 25 mg tablet will be administered once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Odalasvir
Description: Odalasvir 25 mg tablet will be administered once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simeprevir
Description: Simeprevir 75 mg capsule will be administered once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simeprevir
Description: Simeprevir 75 mg capsule will be administered once daily.
Study: NCT03860038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TJ202 and Dexamethasone
Description: one dose of TJ202 16 mg/kg or an adjusted dose will be administered on Day 1 and Day 4 of Week 1, then every week from Week 2 to Week 12, then every 2 weeks from Week 13 to Week 24 and then every 4 weeks thereafter, until the subjects experience an onset of endpoint events like intolerance or PD. DEX 40 mg will be administered on Day 1 and Day 4 of Week 1, respectively and then 40mg weekly thereafter.
Study: NCT05657600

Intervention type: BEHAVIORAL
Intervention: Sociodemographic profile, quality of life, sleep, fatigue, physical function and balance assessments
Description: Respiratory functions are assessed with a portable spirometer according to the criteria of the American Thoracic Society and European Respiratory Society. Measures the physical, mental, social, and environmental well-being were tested to understand the quality of life. The quality of sleep, delayed sleep, sleep disorders, usage of sleeping pills, and loss of functionality during the day were assessed. The balance and static standing capability of the participants were tested. The functional reach of participants were tested by expecting them to lean forwardly as far as they can without taking a step, nor rising their heels. The fatigue feeling of the participants as everyday life were assessed. The posture of the participants was assessed on 13 regions at anterior, posterior and lateral views.

Intervention type: BEHAVIORAL
Intervention: Sociodemographic profile, quality of life, sleep, fatigue, physical function and balance assessments
Description: Respiratory functions are assessed with a portable spirometer according to the criteria of the American Thoracic Society and European Respiratory Society. Measures the physical, mental, social, and environmental well-being were tested to understand the quality of life. The quality of sleep, delayed sleep, sleep disorders, usage of sleeping pills, and loss of functionality during the day were assessed. The balance and static standing capability of the participants were tested. The functional reach of participants were tested by expecting them to lean forwardly as far as they can without taking a step, nor rising their heels. The fatigue feeling of the participants as everyday life were assessed. The posture of the participants was assessed on 13 regions at anterior, posterior and lateral views.
Study: NCT04449133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD128
Description: Oral administration of two capsules before sleep for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral administration of two capsules before sleep for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral administration of two capsules before sleep for 7 days.
Study: NCT03581253

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Facial disability Index (FDi)
Description: questionnaires regarding to quality of life

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Facial Clinimetric Evaluation (FaCE)
Description: questionnaires regarding to quality of life
Study: NCT03512288

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multivalent
Description: Pneumococcal conjugate vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 13vPnC
Description: Pneumococcal conjugate vaccine
Study: NCT04242342

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Adaptative MR-Guided Stereotactic Body Radiotherapy
Description: If lesion near organs at risk:~* Prescription of 50 Gy in 5 fractions of 10 Gy~* 3 sessions per week, with MRI guided stereotactic radiotherapy and daily adaptive treatment~If lesion far of organs at risk:~* Prescription of 60 Gy in 6 fractions of 10 Gy~* 3 sessions per week, with MRI guided stereotactic radiotherapy without daily adaptive treatment
Study: NCT03910296

Intervention type: BEHAVIORAL
Intervention: Acceptance & Commitment Therapy
Description: ACT is a unique, third-wave therapy that uses metaphors and experiential exercises to encourage contact with previously avoided thoughts, feelings, and behaviors.
Study: NCT03672383

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BAY987534
Description: Form: cream; Route of Administration: topical; Frequency of Administration: twice daily ; Duration of Treatment: 4 weeks .
Study: NCT03716583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: 25 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimethyl Sulfoxide
Description: 150 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: 1 g
Study: NCT01208870

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Variety Group
Description: The intervention will consist of our traditional family based weight control intervention with elements of reducing variety of high energy dense foods for the variety group.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition Education Control
Description: The intervention will consist of our traditional family based weight control intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition Education Control
Description: The intervention will consist of our traditional family based weight control intervention.
Study: NCT03792893

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ergometry H
Description: After a pre-rest period of 12 minutes, the subjects are physically strained on the ergometer for 48 minutes (6 minutes loading phase followed by a 2-minute rest phase; 30 watts increase every 8 minutes up to a maximum load of 180 watts), followed by a 12-minute rest periodmaximum load of 180 watts), followed by a 15-minute post-rest period.~BOSO-TM-2430 blood pressure cuff is applied to the upper arm with the previously determined higher systolic blood pressure (reference parameter).~SOMNOtouchTM RESP and GeTeMed Vitaguard 3100 are accordingly applied to the arm with the previously determined lower systolic blood pressure.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ergometry L
Description: After a pre-rest period of 12 minutes, the subjects are physically strained on the ergometer for 48 minutes (6 minutes loading phase followed by a 2-minute rest phase; 30 watts increase every 8 minutes up to a maximum load of 180 watts), followed by a 12-minute rest periodmaximum load of 180 watts), followed by a 15-minute post-rest period.~BOSO-TM-2430 blood pressure cuff is applied to the upper arm with the previously determined lower systolic blood pressure (reference parameter).~SOMNOtouchTM RESP and GeTeMed Vitaguard 3100 are accordingly applied to the arm with the previously determined higher systolic blood pressure.
Study: NCT03030105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPN14770
Description: investigational drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPN14770
Description: investigational drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPN14770
Description: investigational drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BPN14770 placebo
Description: placebo
Study: NCT05657600

Intervention type: OTHER
Intervention: Video-based yoga
Description: Video-based yoga

Intervention type: OTHER
Intervention: Face-to-face yoga
Description: Face-to-face yoga

Intervention type: OTHER
Intervention: physical exercise
Description: physical exercise
Study: NCT03108599

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Cab
Description: The enhanced cab intervention includes the introduction of an active suspension seat and a therapeutic mattress system. After a baseline phase, the intervention arm will receive the enhanced cab intervention alone, and then the enhanced cab plus a behavioral sleep program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fit4Sleep
Description: The behavioral sleep program includes a friendly dyad-based physical activity competition; self-monitoring and logging of physical activity, sleep hygiene behaviors, and sleep; and individual coaching. The behavioral sleep program includes an optional body weight management component. The intervention arm will receive the behavioral sleep program in combination with the enhanced cab intervention.
Study: NCT00664859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCP-AtorFen
Description: All subjects will be assigned to receive open-label LCP-AtorFen combination therapy for 52 weeks. Subjects will take a single oral dose of study drug in the evening without regard to meals.
Study: NCT05015140

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: musıc therapy
Description: calm music with nature sounds set by the music therapist
Study: NCT02737631

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chameleon Personal Lubricant